High titer antibodies against melanoma differentiation antigens (TRP1/TYRP1, TRP2/TYRP2, gp100, MelanA/MART1) were observed in responder group of melanoma patients treated with ICI mAbs (monotherapies with Nivolumab, Pembrolizumab or Ipilimumab, or the combination of Nivolumab and Ipilimumab)28,29. This evidence concerns the gene DCT and melanoma.